GlassScriptPhysician profile
Amber Nichelle Struble
NPI 1952023020
$2,951.13
in general payments reported to CMS, 2019-2025
16 companies · $1,121 in 2025
The $1,121 reported for 2025 was more than what 82% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $120 · 2023: $982 · 2024: $727 · 2025: $1,121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,831.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,830.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $638.00 | 2023-2025 | Caplyta |
| Abbvie INC. | $515.10 | 2023-2025 | |
| Alkermes, INC. | $465.31 | 2022-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $244.30 | 2023-2025 | Spravato, Caplyta, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $233.15 | 2023-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Takeda Pharmaceuticals U.S.A., INC. | $166.54 | 2022-2024 | Trintellix |
| Lundbeck LLC | $137.75 | 2023-2025 | Rexulti, Abilify Maintena |
| Neurocrine Biosciences, INC. | $130.78 | 2023-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $116.66 | 2023-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $74.18 | 2025 | Qelbree |
| Tris Pharma INC | $65.15 | 2023-2024 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $56.04 | 2024 | |
| Vanda Pharmaceuticals INC. | $48.58 | 2022-2025 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $24.50 | 2025 | Cobenfy |
| Corium, LLC | $19.09 | 2022-2025 | Azstarys |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $16.00 | 2023 | Belsomra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Struble listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.